StreetInsider.com News Articles

Form 424B5 bioAffinity Technologies

Mon, 02 Nov 2026 16:52:00 -0500

si-local-file:///var/storage/secattach/20261102/27274852.html

Form 8-K bioAffinity Technologies For: Oct 29

Thu, 29 Oct 2026 08:31:00 -0500

si-local-file:///var/storage/secattach/20261029/27253708.html

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

Thu, 29 Oct 2026 08:00:00 -0500

Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" Event

SAN ANTONIO--(BUSINESS WIRE)-- In recognition of National Lung Cancer Awareness Month, bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for early lung cancer detection with its noninvasive CyPath® Lung test, will join physicians, patients and other healthcare providers at the Lung Cancer Initiative of North Carolina’s Battle of the Blues, an event that will highlight advancements in

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

Thu, 29 Oct 2026 08:00:00 -0500

Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" Event

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

Thu, 29 Oct 2026 08:00:00 -0500

Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" Event

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

Thu, 29 Oct 2026 08:00:00 -0500

Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" Event

Form DEF 14A bioAffinity Technologies For: Oct 23

Fri, 23 Oct 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20261023/27228203.html

Form 8-K bioAffinity Technologies For: Oct 15

Thu, 15 Oct 2026 09:30:00 -0500

si-local-file:///var/storage/secattach/20261015/27191125.html

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0500

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

Presentation to address current challenges in pulmonary nodule management and to discuss preliminary research data from the ongoing development of a new, investigational test for asthma and COPD

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, will sponsor a Learning Theater presentation at

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0500

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0500

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0500

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

Form 8-K bioAffinity Technologies For: Oct 13

Tue, 13 Oct 2026 09:23:00 -0500

si-local-file:///var/storage/secattach/20261013/27178782.html

Form PRER14A bioAffinity Technologies

Tue, 13 Oct 2026 06:09:00 -0500

si-local-file:///var/storage/secattach/20261013/27176391.html

Form 8-K bioAffinity Technologies For: Oct 08

Fri, 09 Oct 2026 16:31:00 -0500

si-local-file:///var/storage/secattach/20261009/27171884.html

bioAffinity Technologies closes $4M stock offering on Nasdaq

Fri, 09 Oct 2026 12:30:16 -0500

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) has closed a registered direct offering of common stock and a concurrent private placement, raising approximately $4 million in gross proceeds before placement agent fees and other expenses, according to a press release from WallachBeth Capital LLC.

The shares were sold to an institutional investor at a purchase price of $6.122 per share, or $6.115 per pre-funded warrant, priced at-the-market under Nasdaq rules. The concurrent private placement included warrants to purchase up to 980,072 shares of common stock at an exercise price of $6.122 per share. The pre-funded warrants carry an exercise price of $0.007

bioAffinity Technologies closes $4M stock offering on Nasdaq

Fri, 09 Oct 2026 12:30:16 -0500

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules